LGVN (Longeveron Corp) יתרות המזומנים של החברה

Longeveron Inc. capital flows are based on the development of anti-aging cell therapies designed to ensure future marginal income. The cash balance clearly confirms the current liquidity level, where 0.01 serves as the current parameter value. Share price growth depends on the success of clinical trials and patent purity, with Lomecel-B trials for Alzheimer's disease acting as the primary catalyst.
פילוחים אנליטיים ודוחות נתונים של חברת Longeveron Inc (LGVN)

Conservative capital demands absolute liquidity transparency to assess business viability during periods of zero revenue. This indicator measures the volume of available cash, allowing investors to calculate the burn rate and forecast the date of a potential cash crunch. For Longeveron Inc., which is developing costly cell therapy, this level of cash reserves confirms the company's ability to fund prolonged clinical trials prior to the commercialization of its patents.